Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- LEN +2.2%, HLF +0.5%, (updates Q3 guidance as part of Herbalife Nutrition's self-tender offer), SPB +0.5%, (reaffirm at investor presentation)
M&A news:
- IZEA +6.9% (provides update on ongoing strategic review process)
- LVLT +3.6% (CenturyLink confirms the DOJ cleared its pending acquisition of Level 3 Communications), CTL +2.5%
Other news:
- ECYT +45.7% (continued momentum; also upgraded at to Outperform at Wedbush)
- VICL +43.8% (FDA has advised that its VL-2397 would be eligible for a Limited Use Indication approval assuming a successful outcome of a single Phase 2 trial carried out in accordance with a protocol and statistical analysis plan consistent with the Agency's advice)
- TA +24.1% (Warren Buffett's Berkshire Hathaway (BRK.A/B) announces investment in travel center Pilot Flying J)
- KOOL +20.3% (announces that the U.S.Patent and Trademark Office has issued a Notice of Allowance regarding the co's pending application for a patent covering a novel method of cell separation)
- DMPI +14% (presents new data suggesting VAL-083 as a potential new therapeutic option in the treatment of ovarian cancer)
- MBRX +8.7% (enters agreement to conduct trial of Annamycin for the treatment of acute myeloid leukemia 'with the first of several hospitals desiring to be treatment centers')
- ACRX +6.5% (continued strength)
- DHXM +4.3% (continued strength after announcing commenced a process to explore and evaluate potential strategic alternatives)
- CNFR +4.2% (announces agreement w/ Swiss Re to cover loss development of up to $17.5 million in excess of stated reserves as of June 30, 2017)
- SAND +2.2% (sold ~14,290 gold equivalent ounces during the third quarter of 2017, the second highest quarterly total in Company history; YTD sale consuistent with FY17 forecast)
- AVXS +2% (will report top-line data from the Phase 1 trial of AVXS-101)
- MDXG +1.2% (extending today's move higher after amending credit agreement - extends the expiration date of the Credit Agreement from October 12, 2018 to October 12, 2019)
- VERI +1.2% (CEO Chad Steelberg discloses 37.9% active stake)
- VNOM +1% (Q3 production increased 20% q/q )
Analyst comments:
- W +3% (attributed to positive comments from sell side shop ahead of Q3 earnings)
- CAMT +2.6% (upgraded to Buy from Hold at Needham)
- GM +1.8% (upgraded to Buy from Neutral at BofA/Merrill)
- PSX +1.7% (upgraded to Buy from Neutral at Goldman)